Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

ginning at 8 P.M. EDT. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 4106309.

Amicus' press releases are available at http://www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease. The Company recently completed Phase I clinical trials of AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

This Press release contains and the accompanying conference call will contain "forward-looking statements" within the meaning of Section 21E of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Examples of such statements include: (i) statements regarding the goals and expected timing of clinical studies, including the effect of the completion of the Phase 2 clinical trial for Amigal for the treatment of Fabry disease, the timing and design of Phase 3 clinical development for Amigal, the Phase 2 clinical trials for Plicera for the treatment of Gaucher disease, the effect of
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... 2014 The Europe Thermal Protective ... to provide crucial revenue forecasts. It estimates the ... at a CAGR of 7.5%, from 2013 to ... Europe Thermal Protective Clothing market report for a ... supported by various tables and figures. , ...
(Date:11/27/2014)... Nov. 27, 2014 Research and ... "Global Palmitic Acid Industry Report 2014" report to ... The Global Palmitic Acid Industry Report 2014 ... state of the global palmitic acid industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:11/27/2014)... 2014 Spartan Bioscience today announced that ... Drug Safety (MFDS) regulatory approval for its Spartan ... in less than 60 minutes from a non-invasive cheek ... aid for doctors to determine therapeutic strategies for drugs ... some of the world’s most commonly prescribed drugs such ...
(Date:11/27/2014)... November 27, 2014 First ...   Elsevier , a world-leading provider ... is pleased to announce the launch of a new ... The launch of Extreme Mechanics ... at the forefront of applied sciences such as micro ...
Breaking Biology Technology:The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3Global Palmitic Acid Industry Report 2014 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 3Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 2Elsevier Announces the Launch of a New Journal: Extreme Mechanics Letters 3
... Inc., today,announced the appointment of Lynn Marcus-Wyner, Ph.D., ... for managing the company,s,intellectual property strategy, activities, and ... President, General Counsel and Secretary., Dr. Marcus-Wyner ... Intellectual Assets US, she managed the United States ...
... Sept. 23 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc.,(TSX: SDI) ... terms with Toray,Industries Inc. of Japan to obtain ... for Toraymyxin(TM), a therapeutic for the treatment of,sepsis ... terms of the,agreement, the Company will seek FDA ...
... BROOMFIELD, Colo., Sept. 23 ARCA biopharma, ... Drug Administration (FDA) has,accepted a New Drug ... bucindolol, an investigational and pharmacologically unique,beta-blocker and ... chronic,heart failure. If approved by the FDA, ...
Cached Biology Technology:Codexis Names Vice President, Intellectual Property 2Spectral to bring anti-sepsis therapy to the U.S. market 2Spectral to bring anti-sepsis therapy to the U.S. market 3FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma 2FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma 3
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
(Date:11/21/2014)... 2014 Strict laws against distracted driving and ... North American and European automotive sector towards gesture recognition ... systems that are intuitive and able to retrieve information ... New analysis from Frost & Sullivan,s ... Europe and North ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... [Brown University] Just as a company creates new, better ... its bottom line, an international team of researchers led by ... and performance before flooding the environment with new, improved versions ... plants with the same ancestor, called a clade, begin to ...
... growth and spread of breast cancer tumors may be ... strategies: blocking the enzyme needed to "energize" cancer cells ... with minimum exposure to healthy tissues, indicate researchers at ... in Chicago, Ill. "Once breast cancer metastases ...
... with information on the size of the carbon footprint ... make better, environmentally friendly choices. A Michigan State ... of the journal Nature Climate Change , said ... with nutritional information, could offer at least a short-term ...
Cached Biology News:Like products, plants wait for optimal configuration before market success 2Interventional radiologists provide hope in delaying growth, spread of breast cancer 2Interventional radiologists provide hope in delaying growth, spread of breast cancer 3Nature paper calls for carbon labeling 2
... genetically engineered Klenow polymerase in which the 3 ... only the 5 to 3 polymerase activity. The ... the enzyme of choice for isotopic or biotin ... method, and for DNA sequencing by the Sanger ...
... a DNA-dependent RNA polymerase which is stringently ... efficiently synthesizes in vitro transcripts from almost ... a T7 promoter. Transcripts can be ... vitro translation, substrates in RNA processing systems, ...
... overproducer ATP: D-hexose 6- phosphotransferase/D-glucose-6-phosphate: ... unit of HK will phosphorylate ... 1 min at 25C at ... G6P-DH will oxidize 1 mol ...
Goat polyclonal to Haptoglobin ( Abpromise for all tested applications). Antigen: Affinity purified human haptoglobin. Entrez GeneID: 3240 Swiss Protein ID: P00738...
Biology Products: